Purpose: The prognostic significance of circulating tumor cells (CTCs) in esophageal carcinoma (EC) is controversial. We aim to assess its association with clinicopathological and prognostic relevance in EC by using a meta-analysis. Methods: We searched PubMed, Cochrane Database, Embase databases, and the references in relevant studies that assessed the clinicopathological or prognostic relevance of CTCs in peripheral blood of patients with EC. Statistical analyses were conducted by using Stata software to calculate the pooled odds ratio (OR), hazard ratio (HR), and 95% confidence intervals (CIs) using fixed or random-effects models according to the heterogeneity of included studies. The subgroup analyses were performed according to ethnicity, histological type, and detection method. Results: Sixteen trials containing 1,260 patients were included for analysis. Pooled results showed that presence of CTCs was significantly associated with poor overall survival (HR = 1.71, 95% CI [1.30, 2.12], P < 0.001) and progression-free survival (HR = 1.67, 95% CI [1.19, 2.15], P < 0.001) in EC patients. Subgroup analysis indicated that presence of CTCs was closely associated with worse overall survival (Asian: HR = 1.66, 95% CI [1.24, 2.08], P < 0.001; squamous cell carcinoma [SCC]: HR = 1.66, 95% CI [1.24, 2.08], P < 0.001; no polymerase chain reaction [PCR]: HR = 2.08, 95% CI [1.40, 2.76], P < 0.001) and progression-free survival (Asian: HR = 1.63, 95% CI [1.15, 2.12], P < 0.001; SCC: HR = 1.63, 95% CI [1.15, 2.12], P < 0.001; PCR: HR = 1.63, 95% CI [1.15, 2.12], P < 0.001). Additionally, ORs showed that presence of CTCs was significantly correlated with tumor node metastasis (TNM) staging (overall: OR = 1.96, 95% CI [1.34, 2.87], P = 0.001; Asian: OR = 2.09, 95% CI [1.37, 3.19], P = 0.001; SCC: OR = 1.97, 95% CI [1.21, 3.07], P = 0.003; PCR: OR = 2.23, 95% CI [1.43, 3.47], P < 0.001), venous invasion (overall: OR = 2.23, 95% CI [1.46, 3.40], P < 0.001; Asian: OR = 2.23, 95% CI [1.46, 3.40], P < 0.001; SCC: OR = 2.23, 95% CI [1.46, 3.40], P < 0.001; PCR: OR = 2.23, 95% CI [1.46, 3.40], P < 0.001), lymph node metastasis (overall: OR = 2.41, 95% CI [1.50, 3.86], P < 0.001; Asian: OR = 2.89, 95% CI [1.80, 4.65], P < 0.001; SCC: OR = 2.44, 95% CI [1.47, 4.07], P = 0.001; PCR: OR = 2.89, 95% CI [1.80, 4.65], P < 0.001) and distant metastasis (Asian: OR = 2.68, 95% CI [1.01, 7.08], P = 0.047) in patients with EC. Conclusion: The presence of CTCs indicates a poor prognosis in EC patients, especially in Asian and SCC patients. Further well-designed prospective studies are recommended to explore the clinical applications of CTCs in patients with EC.